Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4551168
Max Phase: Preclinical
Molecular Formula: C34H54N6O11
Molecular Weight: 722.84
Molecule Type: Unknown
Associated Items:
ID: ALA4551168
Max Phase: Preclinical
Molecular Formula: C34H54N6O11
Molecular Weight: 722.84
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CN1C(=O)[C@H]([C@H](O[C@@H]2O[C@H](CN)[C@@H](O)[C@H]2O)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)N(C)CC=C1C(=O)NC1CCCCCCCCCCC1
Standard InChI: InChI=1S/C34H54N6O11/c1-38-16-14-20(30(46)36-19-12-10-8-6-4-3-5-7-9-11-13-19)39(2)31(47)23(38)28(51-33-27(45)24(42)21(18-35)49-33)29-25(43)26(44)32(50-29)40-17-15-22(41)37-34(40)48/h14-15,17,19,21,23-29,32-33,42-45H,3-13,16,18,35H2,1-2H3,(H,36,46)(H,37,41,48)/t21-,23+,24-,25+,26-,27-,28+,29+,32-,33+/m1/s1
Standard InChI Key: DHIBJKQVLNIKTC-AFHNBZIUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 722.84 | Molecular Weight (Monoisotopic): 722.3851 | AlogP: -1.61 | #Rotatable Bonds: 8 |
Polar Surface Area: 242.14 | Molecular Species: BASE | HBA: 14 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.70 | CX Basic pKa: 8.75 | CX LogP: -1.03 | CX LogD: -2.20 |
Aromatic Rings: 1 | Heavy Atoms: 51 | QED Weighted: 0.16 | Np Likeness Score: 0.66 |
1. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G.. (2019) Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY., 171 [PMID:30933853] [10.1016/j.ejmech.2019.01.071] |
2. Arbour CA,Imperiali B. (2020) Uridine natural products: Challenging targets and inspiration for novel small molecule inhibitors., 28 (18): [PMID:32828427] [10.1016/j.bmc.2020.115661] |
Source(1):